Exhibit 99.2
FOR IMMEDIATE RELEASE
Contact: | Adam C. Derbyshire | G. Michael Freeman | ||||
Executive Vice President and Chief Financial Officer | Associate Vice President, Investor Relations and Corporate Communications | |||||
919-862-1000 | 919-862-1000 |
SALIX PHARMACEUTICALS TO PRESENT AT
THREE INVESTMENT CONFERENCES IN MARCH
RALEIGH, NC, February 22, 2010 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at three health care investment conferences during March 2010. Information on these conferences is provided below:
RBC Capital Markets Healthcare Conference | ||||
New York, NY | Tuesday, March 2 | 3:35 p.m. ET |
Cowen and Company 30th Annual Health Care Conference | ||||
Boston, MA | Wednesday, March 10 | 10:15 a.m. ET |
Roth 22nd Annual Orange County Growth Stock Conference | ||||
Dana Point, CA | Tuesday, March 16 | 5:30 p.m. ET |
Interested parties can access a live audio web cast of these presentations athttp://www.salix.com. A replay of the presentations will be available at the same location.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any
required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team.
Salix markets XIFAXAN® (rifaximin) tablets 200 mg, MOVIPREP® (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), OSMOPREP® (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets,), VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets, APRISO™ (mesalamine) extended-release capsules 0.375 g., METOZOLV™ ODT (metoclopramide HCl), PEPCID® (famotidine) for Oral Suspension, Oral Suspension DIURIL® (Chlorothiazide), AZASAN® Azathioprine Tablets, USP, 75/100 mg, ANUSOL-HC® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Budesonide foam, crofelemer and rifaximin for additional indications are under development.
For full prescribing information, including BOXED WARNINGS for VISICOL, OSMOPREP and METOZOLV, on Salix products, please visitwww.salix.com or contact the Company at 919-862-1000.
Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP.”
For more information please visit our web site atwww.salix.com. Information on our web site is not incorporated in our SEC filings.